Immunoglobulin gene rearrangement (in malignant B cell)

**Immunoglobulin gene rearrangement** refers to the somatic recombination of immunoglobulin (antibody) gene segments (including IGH, IGK, and IGL) in B cells, generating the diversity of the B cell receptor (BCR) repertoire. In malignant B cells, such as in various B-cell lymphomas and leukemias, these genetic rearrangements become clonal, serving as molecular fingerprints of the malignant population. Detecting immunoglobulin gene rearrangements is widely used for the diagnosis and monitoring of B-cell malignancies, including distinguishing between malignant and reactive lymphoid proliferations and assessing minimal residual disease[1][5][7]. However, **immunoglobulin gene rearrangement** is a molecular event or testable biomarker, not a discrete, druggable molecular target or receptor. Drugs do not interact with the gene rearrangement itself, but may target the downstream B cell receptor protein product, B cell signaling pathways, or the malignant clone identified by its rearrangement[3][8]. As such, this entry is **not** a receptor, enzyme, transporter, or any standard "therapeutic target," but rather a fundamental genomic modification at the DNA level used for molecular pathology. **Note:** - This entry is **not a molecular target in the canonical sense** (such as B-cell receptor or specific gene/protein), but a description of a genetic phenomenon characteristic of B cell malignancies. For therapeutic or drug-target purposes, the correct target is either the B-cell receptor or associated signaling proteins[2][3][8]. - If you are looking for an actionable molecular drug target, refer to **B-cell receptor (BCR)** or specific B cell surface proteins involved in signaling. - There is **nothing misspelled**, but the entry is *not a drug target*; rather, it's a biomarker and molecular diagnostic tool.

Other names

Immunoglobulin heavy chain gene rearrangementIgH gene rearrangementImmunoglobulin kappa chain gene rearrangementImmunoglobulin light chain gene rearrangementB cell immunoglobulin rearrangement